39results about How to "High clinical practical value" patented technology

The invention discloses a hand back vein injection instrument based on an infrared imaging technology. The injection instrument comprises a control panel, an infrared imaging part, a mechanical injection part, a fixed part and an instrument framework, wherein a horizontal adjusting rod in the mechanical injection part is parallel with two horizontal sliding rods, and is positioned above a center line position of a rectangle formed by four stepping motors; an injection rod is respectively connected with the horizontal adjusting rod and the horizontal sliding rods; 5 stepping motors are respectively connected with a stepping motor driving module; the stepping motor driving module is connected with a single chip microcomputer; the single chip microcomputer is connected with a computer through a digital serial port. The injection instrument is convenient for adjusting of the injection angle, greatly improves the injection stability of the injection rod, can help patients and medical care personnel to remove the interference of human factors, so as to rapidly and accurately accomplish vein injection, and improves the success rate of hand back vein puncture.

The invention provides a kit for immunoassay determining for small-particle size homogeneous sol particle type cystatin C and a preparation method therefor. The kit can be used for detecting the content of cystatin C in serum or blood plasma. The particle diameter of colloidal gold of the kit for the immunoassay determining for the homogeneous sol particle type cystatin C is 26 to 32nm. The kit has the characteristics of high sensitivity and high stability.

The invention discloses an intelligent diagnostic device of a portable family signing general practitioner. The intelligent diagnostic device comprises mainboard hardware and a software system run on the mainboard hardware; the software system comprises a BSP (board support package) sub system for driving and packaging hardware resources; the BSP sub system for driving and packaging the hardware resources is respectively connected with an embedded operating system, a database subsystem and the mainboard hardware; the embedded operating system and the database subsystem are respectively connected with an application program system through a platform package layer; the embedded operating system and the database subsystem are used for providing uniform and standard programmatic interfaces for the upper application program system through the abstraction of the platform package layer. The intelligent diagnostic device disclosed by the invention is used for family diagnosis and diagnosis and gratuitous diagnosis in other public occasions, the product is positioned on various big hospitals and community health centers; the device is mainly used for gratuitous diagnosis and emergency treatment in the hospitals, and mainly used for community healthcare service and family visit. The product has the features of being complete in function and convenient for use.

The invention discloses an atomization device of a breathing machine. A bottle body is provided with an atomizer outlet and an atomizer inlet, a bottle cap is connected with the bottle body, the bottle cap is provided with an air inlet tube, the air inlet tube is connected with an atomization tube, and the atomization tube is connected with an atomization suction tube; and a reversing valve is arranged on the air inlet tube, the control end of the reversing valve is communicated with the atomizer outlet and the atomizer inlet, and a restrictor ring is arranged in the atomizer outlet or the atomizer inlet. By arranging the reversing valve on the air inlet tube, the atomization device of the breathing machine realizes consistency of atomized oxygen supply and breathing, avoids the waste of atomized medicinal liquid, and prevents the atomized medicinal liquid from corroding the breathing machine. The atomization device has low manufacturing cost so as to greatly reduce the burden of a patient, and is convenient to connect and simple to operate.

The invention discloses a degradable medical polymer material. The degradable medical polymer material is prepared from, by weight, 30-40 parts of vinyl-modified star polylactic acid, 3-6 parts of diacetone acrylamide, 3-6 parts of 1-vinylimidazole, 10-15 parts of a vinyl-terminated hyperbranched polyester, 25-35 parts of a vinyl-terminated polycaprolactone diol and 2,5-furandicarboxylic acid condensation polymer and 1-2 parts of an initiator. The invention also discloses a preparation method of the degradable medical polymer material. The degradable medical polymer material disclosed in the invention has the advantages of good tissue applicability, good degradable metabolism ability, stable quality, excellent mechanical properties, and effectiveness in killing pathogens to prevent the breeding of pathogens.

The invention discloses a fusing protein of long-effective recombinant human exoerythrocytic growing factor, which is characterized by the following: connecting two or three same genes of exoerythrocytic growing factor through one or two sections; constructing mammal expression plasmid; transmitting the plasmid in the mammal cell to express; lengthening the reserving time in the biological body for protein; reducing drug feeding times; improving the clinic practical value.

The invention discloses a pneumoperitoneum no-injury aspirator head end device for a laparoscope. The head end device comprises a suction tube, a control valve, a dipping sponge ball and a sponge ball controller. The suction tube is of a middle bracket structure with the back end communicated with the inner cavity of the control valve; the headmost end of the suction tube and the dipping sponge ball are connected, and the headmost end of the suction tube and the dipping sponge ball are screwed by screw threads and are in sealed connection. The dipping sponge ball comprises outer side conical brackets, a connecting webbing membrane between the conical brackets, elastic sponges in the conical brackets and an arc-shaped top constituted by a front-end unidirectional water-permeable composite fiber membrane, so that the unidirectional circulation of sucked peritoneal fluid is guaranteed, the backflow of dipped liquid is prevented and the possibility that a pneumoperitoneum is injured is reduced. The sponge ball controller, which sleeves outside the dipping sponge ball, can be used for controlling the opening/closing of the dipping sponge ball and facilitating the placement or the withdrawal of the pneumoperitoneum no-injury aspirator head end device for the laparoscope from an abdominal puncture hole. The device disclosed by the invention is relatively suitable for gas laparoscopic operations.

The invention relates to anorectal postoperative fixing trousers, which belongs to the technical field of medical treatment. The fixing trousers are convenient and practical, ventilation is better facilitated, the use comfort of a patient is improved, the dressing can be tightly attached to crissum skin, and recovery of the patient is facilitated. A drainage tube can be installed on the fixing trousers through threads and can also be detached from the fixing trousers to be used according to needs. When the drainage tube is used on the day of an operation, a main tube can effectively assist a postoperative patient in exhausting, observing drainage and judging whether bleeding occurs; on the other hand, liquid is injected through the tail portion of a first branch pipe, the balloon at the front end is bulged, the effects of fixing and compression hemostasis are achieved, and primary bleeding of the postoperative high-position wound surface is well prevented; and on the other hand, a second branch pipe is convenient for postoperative flushing and probing, and hemostatics, therapeutic drugs and the like are convenient to perfuse, and then only the sterile dressing is used, the steriledressing is also detachable, the sterile dressing is adhered to the fixed pants body, and the sterile dressing can be replaced as required.

The invention discloses a medical ultrasonic patch, which is characterized by being composed of the following components (by mass): 7 to 11 percent of hyperbranched chitosan polysaccharideco co-modified by 6-(chloromethyl) uracil/2-(chloromethyl) allyl-trimethylsilane, 1 to 3 percent of lambda-carrageenan, 0.1 to 0.3 percent of zeatin, 0.5 to 1 percent of citronellyl methylcrotonate, 0.01 to 0.02percent of a water-soluble initiator, 0.2 to 0.4 percent of malvidin chloride, 0.8 to 1.5 percent of glycerinum and the balance of deionized water. The invention further discloses a preparation methodof the medical ultrasonic patch. The medical ultrasonic patch disclosed by the invention is convenient and sanitary to use, easy to accept by a patient, high in ultrasonic image quality, reliable indisinfection and sterilization effect, free of corrosion to a probe, stable in physicochemical property, capable of effectively preventing cross infection and relatively good in skin nourishing effect.

The invention discloses a hemostatic material for infants. The hemostatic material is characterized by being prepared from the following raw materials in parts by weight: 5 to 10 parts of a sodium-beta-cyclodextrin metal organic framework, 50 to 60 parts of 4-hydroxybutyl acrylate glycidyl ether-modified hyperbranched polylysine, 1 to 2 parts of allyl B-D glucopyranoside-modified graphene quantumdots, 8 to 12 parts of incense ash, 1 to 3 parts of 4-methacrylamide salicylic acid, 0.5 to 1.5 parts of a coupling agent and 0.05 to 0.08 part of an initiator. The invention also discloses a preparation method of the hemostatic material for infants. The hemostatic material for infants disclosed by the invention is remarkable in hemostatic effect, high in hemostatic efficiency, small in irritationto infant tissues, high in safety and small in toxic and side effects, and has a relatively high clinical practical value.

The invention discloses a method for identifying natural antigen peptide extracted from tissue by using an HLA-I candidate peptide library. The method comprises the following steps: S1, constructing the HLA-I candidate peptide library; S2, identifying the HLA-I type molecule related peptide compound by high-throughput mass spectrometry; S3, identifying the HLA-I type molecule related peptide compound based on the HLA-I candidate peptide library; S4, identifying the HLA-I genotype of the sample; and S5, screening an HLA-I type molecule related immune peptide group based on the binding force of the candidate peptide and the HLA-I type molecule. According to the method, the blank of a special database for identifying the immune peptide group by mass spectrometry is filled, and the problems of overlarge search space and high error occurrence rate during high-throughput mass spectrometry identification of the HLA-I type molecule related peptide group due to database mismatching are solved; the clinical difficulty caused by HLA-I genotype polymorphism distribution of a patient is overcome, and individualized identification of an immune peptide group is realized; the method effectively improves the accuracy and efficiency of high-throughput mass spectrum identification of HLA-I type molecule related immune peptide groups, provides an efficient and reliable method for research and development of tumor individualized therapeutic vaccines, and has very high clinical practical value.

The invention discloses clysis fluid for treating the diabetic nephropathy. The clysis fluid is prepared from, by weight, 25-35 parts of rhizoma imperatae, 25-35 parts of fructus kochiae, 15-25 parts of pterocephalus hookeri heck, 25-35 parts of angelica sinensis, 25-35 parts of buddleja lindleyana, 15-25 parts of endothelium corneum gigeriae galli, 15-25 parts of scutellariae barbatae, 5-15 parts of hirudo, 5-15 parts of liquidambar formosana hance, 5-15 parts of flos magnoliae, 15-25 parts of oroxylum indicum vent, 25-35 parts of rhizoma chuanxiong and 5-15 parts of rosa laevigata michx. According to the application, clysis is conducted before users sleep every night, about 200 ml of clysis fluid is used each time, the treatment course includes 15 days, and clysis is conducted twice every day for users suffering from severe symptoms. The clysis fluid can delay the progress of the diabetic nephropathy, can be the important measure for expectant treatment of the diabetic nephropathy azotemia, and has quite high clinical practical value.

The invention discloses a low-temperature plasma peripheral nerve conditioning method for treating herpes zoster neuralgia and relates to the technical field of medicine. After local infiltration anesthesia by subcutaneous local infiltration anesthesia, a No.12 puncture needle is inserted at 15 degrees subcutaneously to be linked with a plasma knife head and a plasma radio frequency machine, the ablation intensity of the radio frequency machine is adjusted to gear 3, the ablation time for each point is electric cutting 5 s and electrocoagulation 5 s, the needle end is moved from side to side during ablation to increase the ablation range, every 0.5 cm is an ablation point, ablation is carried out while needle withdrawing until pain parts are all ablated, ablation is ended, dressing is applied locally, and surgical sites are kept clean and dried for 48 h. Treated targets are peripheral nerves, by stimulation conditioning of peripheral nerves, the purpose of suppressing abnormal discharge of peripheral nerves is achieved, so that pain is controlled, and the method is reliable in therapeutic effect, simple and safe to operate and higher in clinical practical values.

The invention relates to an atypical antipsychotic medicinal composition. The medicinal composition contains active components risperidone and sertraline hydrochloride according to a weight ratio of 0.04:1 to 0.08:1, and is applied to the treatment of SCZ when the dosage of risperidone in the active components is 2-4 mg/d. Low-dosage risperidone and sertraline hydrochloride in the medicinal composition have excellent synergistic effects; and compared with medium and high dosage risperidone, the medicinal composition has the advantages of equivalent positive symptom elimination effect, significant elimination of negative symptoms and emotion symptoms, and improvement of the social function of SCZ patients when used in the treatment of SCZ. The medicinal composition greatly reduces the occurrence probability of medium and high dosage risperidone induced hyperprolactinemia, severe extrapyramidal symptoms and other adverse drug events.

The invention discloses a primer combination and method for screening high-risk subtypes of acute lymphocytic leukemia. The primer combination comprises 55 pairs of Taqman probes and primers for fusion gene detection and 125 pairs of primers for detection of 206 mutation sites. According to the method, the high-risk subtype of the acute lymphocytic leukemia is screened by adopting a multiplex PCRtechnology and a high-throughput sequencing technology. The invention aims at common and latest molecular abnormalities of high-risk subtypes of acute lymphocytic leukemia, meanwhile, detection of fusion genes and gene mutation is carried out; the primer combination and method have the advantages of being comprehensive in range, high in accuracy and high in specificity, the amount of RNA and DNA needed for detection is low, the requirement can be met through one-time blood sampling, clinical operability is high, acute lymphocytic leukemia high-risk subtype related molecular abnormalities can be rapidly and sensitively detected, and clinical screening is guided.